Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial
European Urology(2022)
摘要
No deterioration in patient-reported outcome scores for health-related quality of life, physical functioning, and symptoms was observed with enfortumab vedotin therapy among patients with locally advanced/metastatic urothelial carcinoma previously treated with platinum-containing chemotherapy and PD-1/PD-L1 inhibitor therapy.
更多查看译文
关键词
Health-related quality of life,Patient-reported outcomes,Enfortumab vedotin,Urothelial cancer
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要